PDA arises when the normal physiological mechanisms triggering ductal constriction after birth fail to operate adequately. Prematurity is a major associated factor, as the immature ductus is less responsive to postnatal rises in oxygen tension. Genetic contributions have been identified; pathogenic variants in TFAP2B are causally linked to Char syndrome, a familial form of PDA. Additional genetic loci associated with isolated familial PDA include those underlying PDA1, PDA2, and PDA3. Environmental exposures during pregnancy, including maternal rubella infection, have been documented as risk factors. The precise interplay between genetic susceptibility and environmental triggers remains an active area of investigation in the literature.

Diagnosis of PDA is established through clinical examination findings, such as a characteristic continuous murmur, supported by imaging. Echocardiography is the principal non-invasive modality documented for confirming ductal patency, characterizing shunt direction and magnitude, and assessing cardiac chamber dimensions. Chest radiography may reveal cardiomegaly and increased pulmonary vascular markings in hemodynamically significant cases. Electrocardiographic findings can reflect ventricular volume overload. In familial or syndromic contexts, genetic evaluation for TFAP2B variants and related loci contributes to etiologic characterization. Cardiac catheterization, though less commonly required for diagnosis alone, provides detailed hemodynamic data when interventional closure is planned.

Pharmacological closure of PDA has been documented using cyclooxygenase inhibitors that reduce prostaglandin-mediated ductal patency. Indomethacin holds FDA NDA approval for PDA management, and ibuprofen lysine (NeoProfen) received FDA NDA approval in 2006 with orphan drug designation from Lundbeck, Inc. Ibuprofen intravenous solution has received orphan drug designation for PDA prevention. For cases where pharmacological treatment is insufficient or contraindicated, surgical ligation and catheter-based ductal occlusion devices represent documented interventional options. In Char syndrome-associated PDA, management of the degree of aorta-to-pulmonary artery shunting guides the choice between conservative, pharmacological, and procedural approaches as described in published literature.

Prognosis in PDA is substantially influenced by ductal size, gestational age at birth, and the presence of associated anomalies or underlying genetic syndromes. Small, asymptomatic PDAs may close spontaneously, particularly in term infants. Hemodynamically significant PDAs that remain unaddressed carry documented risks of progressive pulmonary hypertension, Eisenmenger physiology, and congestive heart failure. In premature neonates, a significant PDA has been associated with increased morbidity including intraventricular hemorrhage and necrotizing enterocolitis in the literature. Following successful pharmacological or procedural closure, the cardiovascular prognosis is generally favorable, though long-term follow-up data continue to be gathered through ongoing clinical trials.

There are currently 21 active or ongoing clinical trials registered for PDA, addressing pharmacological strategies, device-based closure, and monitoring technologies. Notable studies include the NICHD Neonatal Research Network's Phase 3 Management of the PDA Trial (NCT03456336), the PREEMIE study evaluating PDA treatment in premature infants (NCT06587282), and a Phase 2 trial examining co-administration of acetaminophen with ibuprofen in extremely premature infants (NCT05340582). Device evaluation studies, including the HeartR PDA Occluder Post-Market Follow-Up Study, are also active. Research into early prediction of spontaneous PDA closure (NCT03782610) and renal outcomes associated with PDA (NCT06658496) reflects the breadth of current investigational activity.